Jan
19
COVID-19 VACCINES
Evaluating the safety, immunogenicity, and efficacy of a next-generation RNA vaccine for COVID-19 prevention
Completed | Phase I–III | COVID-19 | ≥18 years
Overview
This study evaluated the safety, immunogenicity, and efficacy of a next-generation RNA vaccine for the prevention of COVID-19 in adults.
Study population (general)
Healthy adult participants.
Principal Investigator
Prof., PhD Tạ Thành Văn et al.
Contact
CTU – Email – Phone
